A recent release by Ponce De Leon Health outlines findings from a large-scale longevity study presented at a Nutritional Business Journal CEO conference, according to the company. The analysis, using AI-driven cross-sectional modeling adjusted for age, sex, smoking and health status, examined 4,260 individuals who purchased saliva-based DNA epigenetic tests between 2020 and 2025 and reported using nearly 900 different longevity products.
According to the company, only Rejuvant—a branded, slow-release calcium-alpha-ketoglutarate (CaAKG) supplement—was statistically associated with reduced biologic age. The reported average Age Delta (biological age minus chronological age) was 5.74 years lower.
The company said that no statistically significant benefits were observed for other tested compounds, including NAD boosters such as nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), carotenoids, metformin, or other forms of CaAKG and AKG.
Dr. Brian Kennedy, the presenting researcher, is described as a distinguished professor at the Yong Loo Lin School of Medicine, National University of Singapore. The company claims that the study has been submitted for publication in a peer-reviewed scientific journal in 2025.
